PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals Finds Frost & Sullivan - Glaucoma therapies offering greater ease-of-use enhance patient compliance and improve uptake
Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2012/04/26 - Glaucoma therapies offering greater ease-of-use enhance patient compliance and improve uptake.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Glaucoma is the second leading cause of blindness in the United States, presenting the glaucoma pharmaceuticals market with a significant opportunity to fulfill unmet medical needs. Being an adult disease, the patient pool for glaucoma will expand as the population ages.

New analysis from Frost & Sullivan’s (pharma.frost.com) Analysis of the United States Glaucoma Pharmaceuticals Market research finds that the market earned revenues of approximately $2.19 billion in 2010 and estimates this to reach $2.25 billion in 2016.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, job title, telephone number, company email address, company Website, city, state and country.

Considering almost 50 percent of the patient population is under-diagnosed and underserved with available pharmacotherapy options, pharmaceuticals that offer effective therapies, improved drug delivery, and higher disease awareness through patient education will be immensely successful.

Additionally, patients suffering from glaucoma, whether they are aware of the disease or not, need therapies better than the numerous pharmacotherapy options available currently.

"The underserved population of patients is not achieving therapy goals and demonstrates poor patient compliance with daily eye drops,” said Frost & Sullivan Industry Analyst Debbie Toscano. "There is considerable need for more effective therapies that go beyond targeting intraocular pressure to preserve optic nerve function, as well as for innovations in delivery to improve patient compliance and clinical outcomes."

So far, the availability of a number of low-cost generic medications, including a generic version of the gold-standard prostaglandin analog (PA), Xalatan, may reduce the attractiveness of this market to potential participants. As glaucoma requires life-long therapy, there is a huge demand for low-cost therapeutic options, which slows down innovation in the market. The increasing economic pressures are also expected to compel payers and prescribers to encourage the use of generics.

However, there is a substantial need for innovation in drug delivery and alternatives to daily eye drops. For example, many patients, particularly the elderly, have difficulty in self-administering them. Eye drops also involve other challenges such as high frequency of administration, wastage of drops, and inability to last for the duration of prescription, leading to non-compliance and under-treatment.

Innovative pharmaceutical and biotech companies seeking to tap into this market have to offer improved therapies exhibiting novel mechanisms and/or delivery methods. Novelty in mechanisms that address the underlying causes of glaucoma and provide additional clinical benefit such as neuroprotection is vital to improve patient outcomes and prevent blindness.

"The heterogeneous nature of the pathophysiology of glaucoma and the variable patient response to therapy drive the need for multiple effective therapeutic choices," said Toscano. “Currently, PAs dominate the market with 59.8 percent of the total share due to their superior efficacy, tolerability and convenience profiles. The introduction of this class to the market has significantly raised the bar for new entrants.”

Analysis of the United States Glaucoma Pharmaceuticals Market is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: U.S. Retinal Therapeutics Market, European Ophthalmic Pharmaceuticals Market, U.S. Glaucoma Pharmaceuticals Market, and 2010 U.S. Ophthalmologists' Assessment of Eye Care Medication Brands. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

Analysis of the United States Glaucoma Pharmaceuticals Market / NA6D-52

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Britni Myers 
210-477-8481 britni.myers[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)